• Access To Financings
  • Transparent
  • Innovative
  • Well-Connected

Starton Therapeutics CEO talks through 2019 achievements and anticipated milestones in 2020

Starton Therapeutics CEO Pedro Lichtinger sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. Lichtinger talks about how the New York-based company recently changed its name from ChemioCare, how the company is well capitalized to continue through Q1 to next year, its anticipate IPO, and recent ‘unprecedented results’ out of its in multiple myeloma therapy.